Merrill Lynch’s stock price bounced nicely at the end of July, up 17% on the day following its sale to Lone Star of $30.6 billion in face value of US super-senior CDOs of ABS for just 22 cents on the dollar. Analysts applauded its bravery in taking this big hit to get out from under its most toxic asset problem rather than creeping along from one quarterly write-down to the next. Stock investors seemed relieved that a big uncertainty has been removed and the US market swallowed the biggest ever follow-on public equity offering of $8.55 billion of Merrill shares in just 15 hours.
Certainly this feels like a watershed deal that has big implications for the rest of the financial industry. But it’s hard to share the stock market’s first-day euphoria.
First of all, it raises an issue of credibility against...
You must be a subscriber to access this archived content.
If your subscription includes access to the archive, please log in now to view.
To gain access to this content visit the subscription page or call our hotline on +44 (0)207 779 8999.
Subscribe online now and save up to 30% on your subscription.
If you are a trialist or subscriber, please enter your username and password at the top right-hand side of euromoney.com
Subscribers to Euromoney benefit from:
- 12 months access in print and online - on euromoney.com, read the latest issue early online, search for specific developments by region or sector, interrogate the results of Euromoney's benchmark polls, and view the archive dating back to 1996
- More than 30 specialist research guides free
- The results of Euromoney’s polls and surveys
- Tailored RSS news feeds direct to your desktop
- News delivered directly to your mobile device or PC
- Personalised email newsfeed of 'Top stories' and 'Breaking news'
Click here to subscribe